Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 106 of the 106 references it cites were found in a registry or an index.

Salmon calcitonin: a review of current and future therapeutic indications

Chesnut, C. H., Azria, M., Silverman, S., Engelhardt, M., Olson, M., Mindeholm, L. · 2008 · Osteoporosis International

Abstract

Salmon calcitonin, available as a therapeutic agent for more than 30 years, demonstrates clinical utility in the treatment of such metabolic bone diseases as osteoporosis and Paget's disease, and potentially in the treatment of osteoarthritis. This review considers the physiology and pharmacology of salmon calcitonin, the evidence based research demonstrating efficacy and safety of this medication in postmenopausal osteoporosis with potentially an effect on bone quality to explain its abilities to reduce the risk of spine fracture, the development of an oral salmon calcitonin preparation, and the therapeutic rationale for this preparation's chondroprotective effect in osteoarthritis.

Overview

Integrity signals

Registry

Crossref · 10.1007/s00198-007-0490-1

Cites

106 of 106 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 106 references

Research works printed but not linked: 8

  1. Woodrow JP, Noseworthy CS, Fudge NJ, Hoff AO, Gagel RF, Kovacs CS (2003) Calcitonin/calcitonin gene-related peptide protect the maternal skeleton from excessive resorption during lactation [abstract]. J Bone Miner Res 18(Suppl 2):S37
  2. Hoff A, Thomas M, Cote G (1998) Generation of a calcitonin knockout mouse model [abstract]. Bone 23:1062
  3. Voss A, Liese S, Priemel M, Catala-Lehnen P, Schilling AF, Mueldner C, Haberland M, Rueger JM, Emeson RB, Gagel RF, Schinke T, Amling M (2005) Uncovering the physiologic function of calcitonin using genetically modified mouse models [abstract]. J Bone Min Res (Suppl.):1162
  4. Chesnut CH, Richardson P, Mindeholm L (2002) Salmon calcitonin nasal spray (SCNS): effect on hip fractures in postmenopausal women [abstract]. Osteoporos Int 13(Suppl 1):128
  5. Olson M, Mindeholm L, Eriksen EF, Majumdar S, Azria M, Chesnut C (2006) Trabecular number as risk factor in osteoporosis and the role of nasal spray calcitonin (NS-CT) in its modification [abstract]. Osteoporos Int 17(Suppl 1):S12–S13
  6. Cranney A, Welch V, Adachi JD, Homik J, Shea B, Suarez-Almazor ME, Tugwell P, Wells G (2000) Calcitonin for the treatment and prevention of corticosteroid-induced osteoporosis. Cochrane Database Syst Rev 2:CD001983
  7. Gennari C, Agnusdei D (1988) Calcitonin in bone pain management. Curr Ther Res 44:712–722
  8. Gennari C, Chierichetti SM, Piolini M, Vibelli C, Agnusdei D, Civitelli R, Gonelli S (1985) Analgesic activity of salmon and human calcitonin against cancer pain: a double-blind, placebo-controlled clinical study. Curr Ther Res 38:298–308

Cited by

See all 228

Metadata

Authors
Chesnut, C. H., Azria, M., Silverman, S., Engelhardt, M., Olson, M., & Mindeholm, L.
Affiliations
  • University of Washington (US)
  • Novartis (Switzerland) (CH)
  • Cedars-Sinai Medical Center (US)
Corresponding author
Chesnut, C. H.
Venue
Osteoporosis International
Published
2007-12-11
Volume
19
Issue
4
Pages
479-491
ISSN
  • 0937-941X (ISSN-L)
  • 1433-2965
OpenAlex
W2069365129
Cited by
216
References
106
Citations by year
2026: 5 · 2025: 16 · 2024: 8 · 2023: 10 · 2022: 17 · 2021: 7 · 2020: 15 · 2019: 10 · 2018: 12 · 2017: 15 · 2016: 12 · 2015: 7 · 2014: 11 · 2013: 14 · 2012: 9
FWCI
1.69
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • Osteoporosis International (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
  • Health Sciences › Medicine › Nephrology › Parathyroid Disorders and Treatments
Keywords
salmon calcitonin, osteoporosis, Paget's disease, osteoarthritis, postmenopausal osteoporosis, bone quality, chondroprotection, metabolic bone disease
MeSH terms
Adult, Aged, Bone Resorption, Calcitonin, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Humans, Middle Aged, Osteitis Deformans, Parathyroid Hormone, Bone Density, Osteoporosis, Postmenopausal, Spinal Fractures, Treatment Outcome, Bone Density Conservation Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Salmon calcitonin: a review of current and future therapeutic indications. https://app.cochat.ai/papers/10.1007/s00198-007-0490-1
The paper
Chesnut, C. H., Azria, M., Silverman, S., Engelhardt, M., Olson, M., & Mindeholm, L. (2008). Salmon calcitonin: a review of current and future therapeutic indications. Osteoporosis International. https://doi.org/10.1007/s00198-007-0490-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.